311 related articles for article (PubMed ID: 15361181)
1. Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer.
Tjalma WA; Arbyn M; Paavonen J; van Waes TR; Bogers JJ
Int J Gynecol Cancer; 2004; 14(5):751-61. PubMed ID: 15361181
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
Rambout L; Hopkins L; Hutton B; Fergusson D
CMAJ; 2007 Aug; 177(5):469-79. PubMed ID: 17671238
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus vaccines versus cervical cancer screening.
Stanley M
Clin Oncol (R Coll Radiol); 2008 Aug; 20(6):388-94. PubMed ID: 18538554
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
5. [Human papillomavirus (HPV) vaccines--a new method for the prevention of cervical cancer].
Friedek DA; Ekiel AM; Martirosian G
Wiad Lek; 2007; 60(1-2):34-8. PubMed ID: 17607966
[TBL] [Abstract][Full Text] [Related]
6. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.
McKeage K; Romanowski B
Drugs; 2011 Mar; 71(4):465-88. PubMed ID: 21395359
[TBL] [Abstract][Full Text] [Related]
7. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
Hantz S; Alain S; Denis F
Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
[TBL] [Abstract][Full Text] [Related]
8. [Preventive vaccines against papillomavirus and cervix cancer will soon enter clinical practice].
Lehtinen M; Malm C; Apter D; Heikkilä R; Heino P; Rimpilä K; Zilliacus R; Paavonen J
Lakartidningen; 2003 Oct; 100(43):3408-12. PubMed ID: 14626768
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.
Harper DM; Franco EL; Wheeler C; Ferris DG; Jenkins D; Schuind A; Zahaf T; Innis B; Naud P; De Carvalho NS; Roteli-Martins CM; Teixeira J; Blatter MM; Korn AP; Quint W; Dubin G;
Lancet; 2004 Nov 13-19; 364(9447):1757-65. PubMed ID: 15541448
[TBL] [Abstract][Full Text] [Related]
10. HPV vaccines.
Stanley M
Best Pract Res Clin Obstet Gynaecol; 2006 Apr; 20(2):279-93. PubMed ID: 16356772
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic HPV vaccines.
Hancock G; Hellner K; Dorrell L
Best Pract Res Clin Obstet Gynaecol; 2018 Feb; 47():59-72. PubMed ID: 29108943
[TBL] [Abstract][Full Text] [Related]
12. Prevention of human papilloma virus infection with vaccines.
Azam F; Shams-ul-Islam M
J Pak Med Assoc; 2010 Aug; 60(8):676-81. PubMed ID: 20726203
[TBL] [Abstract][Full Text] [Related]
13. [Vaccination against human papilloma virus and cervical cancer].
Kidon MI; Shechter E; Toubi E
Harefuah; 2011 Jan; 150(1):33-6, 68. PubMed ID: 21449154
[TBL] [Abstract][Full Text] [Related]
14. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
15. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.
Harper DM; Franco EL; Wheeler CM; Moscicki AB; Romanowski B; Roteli-Martins CM; Jenkins D; Schuind A; Costa Clemens SA; Dubin G;
Lancet; 2006 Apr; 367(9518):1247-55. PubMed ID: 16631880
[TBL] [Abstract][Full Text] [Related]
16. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
17. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
18. Cervical cancer, human papillomavirus and vaccines.
Khan SA
Clin Oncol (R Coll Radiol); 1993; 5(6):386-90. PubMed ID: 8305362
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
Kaufmann AM; Stern PL; Rankin EM; Sommer H; Nuessler V; Schneider A; Adams M; Onon TS; Bauknecht T; Wagner U; Kroon K; Hickling J; Boswell CM; Stacey SN; Kitchener HC; Gillard J; Wanders J; Roberts JS; Zwierzina H
Clin Cancer Res; 2002 Dec; 8(12):3676-85. PubMed ID: 12473576
[TBL] [Abstract][Full Text] [Related]
20. Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines.
Einstein MH
Cancer Immunol Immunother; 2008 Apr; 57(4):443-51. PubMed ID: 18157723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
